UB Paderborn / Katalog / Suche / in CDI

Patient‐reported reasons for discontinuing overactive bladder medication

BJU international, 2010-05, Vol.105 (9), p.1276-1282

2010

Link zum Volltext

Verfügbarkeit prüfen

Amikacin liposome inhalation suspension clinical benefit–risk assessment for refractory Mycobacterium avium complex lung disease

ERJ open research, 2022-07, Vol.8 (3), p.623

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women

International Urogynecology Journal, 2008-11, Vol.19 (11), p.1551-1557

2008

Link zum Volltext

Verfügbarkeit prüfen

CULTURE CONVERSION AND MORTALITY IN PATIENTS WITH MYCOBACTERIUM AVIUM COMPLEX LUNG DISEASE: A SYSTEMATIC REVIEW

Chest, 2020-10, Vol.158 (4), p.A312-A312

2020

Link zum Volltext

Verfügbarkeit prüfen

RELATIONSHIP BETWEEN CULTURE CONVERSION AND CLINICAL OUTCOMES IN MYCOBACTERIUM AVIUM COMPLEX LUNG DISEASE: A SYSTEMATIC REVIEW

Chest, 2020-10, Vol.158 (4), p.A315-A315

2020

Link zum Volltext

Verfügbarkeit prüfen

Retrospective evaluation of outcomes in patients with overactive bladder receiving tolterodine versus oxybutynin

American journal of health-system pharmacy, 2006-12, Vol.63 (23), p.2357-2364

2006

Link zum Volltext

Verfügbarkeit prüfen

Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection

Journal of cystic fibrosis, 2021-11, Vol.20 (6), p.1010-1017

2021

Link zum Volltext

Verfügbarkeit prüfen

Amikacin liposome inhalation suspension for Mycobacterium avium complex pulmonary disease: A subgroup analysis of Japanese patients in the randomized, phase 3, CONVERT study

Respiratory investigation, 2024-03, Vol.62 (2), p.284-290

2024

Link zum Volltext

Verfügbarkeit prüfen

Bother related to bladder control and health care seeking behavior in adults in the United States

The Journal of urology, 2009-06, Vol.181 (6), p.2591

2009

Link zum Volltext

Verfügbarkeit prüfen

PRO Data Collection in Clinical Trials Using Mixed Modes: Report of the ISPOR PRO Mixed Modes Good Research Practices Task Force

Value in health, 2014-07, Vol.17 (5), p.501-516

2014

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency

The Journal of urology, 2013-04, Vol.189 (4), p.1396

2013

Link zum Volltext

Verfügbarkeit prüfen

1468. Culture Conversion and Mortality in Patients With Mycobacterium abscessus (MAB) Lung Disease: A Systematic Literature Review

Open forum infectious diseases, 2020-12, Vol.7 (Supplement_1), p.S736-S736

2020

Link zum Volltext

Verfügbarkeit prüfen

1488. Relationship Between Culture Conversion and Clinical Outcomes in Patients With Mycobacterium abscessus (MAB) Lung Disease: A Systematic Literature Review

Open forum infectious diseases, 2020-12, Vol.7 (Supplement_1), p.S746-S746

2020

Link zum Volltext

Verfügbarkeit prüfen

Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects

British journal of clinical pharmacology, 2011-08, Vol.72 (2), p.263-269

2011

Link zum Volltext

Verfügbarkeit prüfen

A Pragmatic Randomized Trial Comparing Telephone-Based Enhanced Pharmacy Care and Usual Care to Support Smoking Cessation

Journal of managed care & specialty pharmacy, 2016-12, Vol.22 (12), p.1417

2016

Link zum Volltext

Verfügbarkeit prüfen

Persistence with overactive bladder pharmacotherapy in a Medicaid population

The American journal of managed care, 2005-07, Vol.11 (4 Suppl), p.S121-S129

2005

Link zum Volltext

Verfügbarkeit prüfen

Predictors of discontinuing overactive bladder medications

BJU international, 2010-05, Vol.105 (9), p.1283-1290

2010

Link zum Volltext

Verfügbarkeit prüfen

Defining urinary urgency: Patient descriptions of "gotta go"

Neurourology and urodynamics, 2012-04, Vol.31 (4), p.455-459

2012

Link zum Volltext

Verfügbarkeit prüfen

Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects : Clinical pharmacology of functional disorders of the urogenital system

British journal of clinical pharmacology, 2011, Vol.72 (2), p.263-269

2011

Link zum Volltext

Verfügbarkeit prüfen

The Validation of Patient-Rated Global Assessments of Treatment Benefit, Satisfaction, and Willingness to Continue—The BSW

Value in health, 2005-11, Vol.8, p.S25-S34

2005

Link zum Volltext

Verfügbarkeit prüfen

Urinary incontinence in the nursing home: resident characteristics and prevalence of drug treatment

The American journal of managed care, 2005-07, Vol.11 (4 Suppl), p.S112-S120

2005

Link zum Volltext

Verfügbarkeit prüfen

Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence

Current medical research and opinion, 2009-09, Vol.25 (9), p.2159-2165

2009

Link zum Volltext

Verfügbarkeit prüfen

The responsiveness of the OAB-q among OAB patient subgroups

Neurourology and urodynamics, 2007-01, Vol.26 (2), p.196-203

2007

Link zum Volltext

Verfügbarkeit prüfen

Meeting the obligation to communicate clinical trial results to study volunteers

Expert review of clinical pharmacology, 2012-03, Vol.5 (2), p.149-156

2012

Link zum Volltext

Verfügbarkeit prüfen

Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder

The American journal of managed care, 2005-07, Vol.11 (4 Suppl), p.S140-S149

2005

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Patient‐reported reasons for discontinuing overactive bladder medication

Amikacin liposome inhalation suspension clinical benefit–risk assessment for refractory Mycobacterium avium complex lung disease

Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women

CULTURE CONVERSION AND MORTALITY IN PATIENTS WITH MYCOBACTERIUM AVIUM COMPLEX LUNG DISEASE: A SYSTEMATIC REVIEW

RELATIONSHIP BETWEEN CULTURE CONVERSION AND CLINICAL OUTCOMES IN MYCOBACTERIUM AVIUM COMPLEX LUNG DISEASE: A SYSTEMATIC REVIEW

Retrospective evaluation of outcomes in patients with overactive bladder receiving tolterodine versus oxybutynin

Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection

Amikacin liposome inhalation suspension for Mycobacterium avium complex pulmonary disease: A subgroup analysis of Japanese patients in the randomized, phase 3, CONVERT study

Bother related to bladder control and health care seeking behavior in adults in the United States

PRO Data Collection in Clinical Trials Using Mixed Modes: Report of the ISPOR PRO Mixed Modes Good Research Practices Task Force

Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency

1468. Culture Conversion and Mortality in Patients With Mycobacterium abscessus (MAB) Lung Disease: A Systematic Literature Review

1488. Relationship Between Culture Conversion and Clinical Outcomes in Patients With Mycobacterium abscessus (MAB) Lung Disease: A Systematic Literature Review

Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects

A Pragmatic Randomized Trial Comparing Telephone-Based Enhanced Pharmacy Care and Usual Care to Support Smoking Cessation

Persistence with overactive bladder pharmacotherapy in a Medicaid population

Predictors of discontinuing overactive bladder medications

Defining urinary urgency: Patient descriptions of "gotta go"

Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects : Clinical pharmacology of functional disorders of the urogenital system

The Validation of Patient-Rated Global Assessments of Treatment Benefit, Satisfaction, and Willingness to Continue—The BSW

Urinary incontinence in the nursing home: resident characteristics and prevalence of drug treatment

Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence

The responsiveness of the OAB-q among OAB patient subgroups

Meeting the obligation to communicate clinical trial results to study volunteers

Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder

Suchergebnisse filtern